Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?

Spreaker is getting a new look!

Preview our new listening experience personalized just for you.

Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?

GRACEcast

00:00

03:50

Like Download

Dr. David Spigel, Sarah Cannon Cancer Center, offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.

Dr. David Spigel, Sarah Cannon Cancer Center, offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years. read more read less

11 years ago #afatinib, #alk, #cancer, #cancergrace, #cannon, #center, #david, #egfr, #grace, #gracecast, #immunotherapy, #inhibitor, #kras, #ldk, #mek, #met, #pd1, #pdl1, #sarah, #spigel

0 Comments

This episode has no messages yet. Be the first to write a message!

Spreaker is getting a new look!

Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?

Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?

0 Comments

For Creators

For Listeners & Advertisers

Choose Language

Follow us